A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens
Liang Zhao, Xiao He, Mingyang Deng, Yun Yuan, Zhiyu Su, Zhongqi Ding, Youping Liao, Chanjuan Shen, Zhongjun Huo, Zimian Luo, Zhiqin Li, Limei Fu, Ping Zhu, Xiangling Feng, Shuping Chen, Yanjuan He, Yan Zhu · 2026
Read A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens by Liang Zhao, Xiao He, Mingyang Deng, Yun Yuan, Zhiyu Su, Zhongqi Ding, Youping Liao, Chanjuan Shen, Zhongjun Huo, Zimian Luo, Zhiqin Li, Limei Fu, Ping Zhu, Xiangling Feng, Shuping Chen, Yanjuan He, Yan Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13601858.txt.
Description
Liang Zhao and sixteen co-authors compare two weekly doses of an oral myeloma drug across six centers in China. Ixazomib is usually started at 4 mg, with 3 mg as the fallback when side effects bite, and both doses sit in the effective range. Records covered 207 patients on ixazomib-based therapy. Groups split by dose and by treatment phase: first use, class switch, or maintenance.
The 3 mg and 4 mg cohorts matched on efficacy in the induction and switch settings in the reported analysis. Toxicity profiles were compared side by side as well. The study helps clinicians judge whether the gentler dose gives up any disease control.
Catalog record
| CREATOR | Liang Zhao, Xiao He, Mingyang Deng, Yun Yuan, Zhiyu Su, Zhongqi Ding, Youping Liao, Chanjuan Shen, Zhongjun Huo, Zimian Luo, Zhiqin Li, Limei Fu, Ping Zhu, Xiangling Feng, Shuping Chen, Yanjuan He, Yan Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |